Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial
Regardless of concomitant alerting agent use, ON-SXB improved daytime and nighttime narcolepsy symptoms vs placebo.
Authors
- Thomas Roth (ORCID: https://orcid.org/0000-0001-8309-4134)
- Anne Marie Morse (ORCID: https://orcid.org/0000-0003-4494-0195)
- Michael J. Thorpy (ORCID: https://orcid.org/0000-0002-3993-2230)
- Jennifer Gudeman (ORCID: https://orcid.org/0000-0002-7375-5020)
- Richard Bogan (ORCID: https://orcid.org/0000-0001-7043-2974)
- Yves A Dauvilliers (ORCID: https://orcid.org/0000-0003-0683-6506)
- Asim Roy
Institutions
- Geisinger Medical Center (US)
- Albert Einstein College of Medicine (US)
- Medical University of South Carolina (US)
- Henry Ford Health System (US)
- Inserm (FR)
- Université de Montpellier (FR)
- Sleep Management Institute (US)
- Institute for Neurosciences of Montpellier (FR)
- Geisinger Commonwealth School of Medicine (US)
- Citadel (US)
Publication Details
- Journal
- Sleep Medicine
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1016/j.sleep.2024.09.024
- Citations
- 3
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 1.03